(BUSINESS WIRE)-- As part of their commitment to help drive innovation in wound care, Systagenixhas teamed up with The World Union of Wound Healing Societies (WUWHS) to create the 2012 Future Innovation in Woundcare Award. The prize, a £10,000 unrestricted educational grant, will be awarded to an individual or organisation that presents the best abstract for a research idea, improvement of current practice or new service that will help advance the field of woundcare.
WUWHS is awarding this prize from the abstracts submitted to the WUWHS 2012 Conference Young Investigators category. Any abstracts that are related to ‘innovative’ and ‘attractive’ are automatically considered for award selection. The winner will need to meet a set of criteria, including that the work will have to be innovative, the project needs to have already started or is planned start immediately and the final results will be presented within September 2013. The judging panel consists of the scientific committee of WUWHS 2012and the winning abstract will be announced at the 4th Congress of the World Union of Wound Healing Societiesin Yokohama, Japan September 2012.
“Within our business environment, Systagenix has a very clear set of vision and values: To develop and market advanced diagnostic and therapeutic systems that enable clinicians to heal every wound predictably and cost effectively. This is the ambition that drives our business and everyone who works here. Hence we are proud to sponsor the WUWHS 2012 Future Innovation in Woundcare Award - brought to you by Systagenix – the home of Let’s Heal®” said Kirsti Harefallet, Head of Global Marketing Communications.
Established in 2008, following the acquisition of Johnson & Johnson’s advanced wound care business, Systagenix supplies over 20 million advanced wound dressings per month into over 100 countries worldwide. The company has just launched the world’s first rapid, point of care diagnostic test developed specifically for chronic wounds, WOUNDCHEK™ Protease Status, which has the potential to revolutionise wound care by enabling early, targeted intervention and cost effective use of advanced therapies designed to modulate protease activity.
Information on Systagenix wound care can be found at www.systagenix.com.
Contacts
VSPR for Systagenix
Vicky Stoakes
Tel +44 (0)7747 534 519
vicky@vs-pr.com
No comments:
Post a Comment